The PubMed entry describes a clinical trial published in Lancet investigating the use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children. The trial title and classification indicate the research focus is prevention of early childhood wheeze using an oral bacterial lysate product that has been studied previously in various respiratory contexts. The available source material for this summary is limited to the PubMed bibliographic record and associated metadata; detailed trial rationale, background literature review, and the biological mechanism of OM-85 are not included in the provided text.
The trial is identified as a randomised, placebo-controlled clinical trial and is indexed as a Clinical Trial in the PubMed record. The publication details are Lancet. 2026 Sep 19;408(10560):1103–1113, DOI 10.1016/S0140-6736(26)01443-1 (Epub 2026 Sep 7). A full author list and institutional affiliations are provided in the PubMed record, showing a multicenter collaboration across pediatric, pulmonology, allergy/immunology, and biostatistics groups in the United States.
The PubMed entry does not include specific trial-site locations, dates of enrollment, randomisation scheme details (for example, allocation ratio or concealment), blinding procedures, or sample size calculations. Those methodological elements were not reported in the supplied source text and must be obtained from the full Lancet article.
The title specifies the trial population as preschool children at risk for wheezing lower respiratory illness, but the PubMed excerpt does not include inclusion or exclusion criteria, age ranges, baseline characteristics, or the number of participants randomized. Information on recruitment settings (primary care, specialty clinics, community), demographic composition, or coexisting conditions is not reported in the provided material.
The intervention named in the title is the bacterial lysate OM-85; the comparator is a placebo as indicated by the study design. The PubMed record does not state the OM-85 dosing regimen, route of administration, schedule, total duration of therapy, formulation, or adherence measures. Details about placebo composition or how the placebo was matched to OM-85 are also not present in the supplied text.
The trial objective in the title is the primary prevention of wheezing lower respiratory illness, implying a primary endpoint related to occurrence or frequency of wheezing episodes or wheeze-associated respiratory illness. However, the PubMed summary provided here does not define the primary or secondary endpoints, case definitions for wheezing lower respiratory illness, methods of outcome ascertainment (caregiver report, physician diagnosis, healthcare utilization), or follow-up duration. These outcome specifications and adjudication processes are not reported in the available source material.
The PubMed bibliographic entry does not include numerical results, effect sizes, confidence intervals, p values, or event rates. The provided source therefore does not permit reporting of whether OM-85 reduced incidence of wheezing lower respiratory illness, the magnitude of any effect, or subgroup differences. The absence of outcome data and statistical findings in the supplied text prevents drawing conclusions about efficacy.
No safety data, adverse event rates, serious adverse events, or tolerability information are included in the PubMed excerpt. The supplied material does not report whether OM-85 was well tolerated, whether adverse events differed from placebo, or whether any safety signals were observed.
From the PubMed metadata alone, it is clear that a randomized, placebo-controlled trial of OM-85 for primary prevention of preschool wheeze has been completed and published in a high-impact journal, involving a multidisciplinary US investigator group. However, because the supplied source text does not include methods, results, or authors’ conclusions, clinical interpretation regarding efficacy, safety, or practice implications cannot be made solely from this record. Clinicians, guideline developers, and researchers should review the full Lancet article for complete data before considering changes to clinical practice.
The text provided here is a bibliographic and navigational PubMed page excerpt that lists title, authors, affiliations, PMID, DOI, and journal citation. It lacks the trial abstract and full-text content needed to summarize trial conduct and findings. Key missing elements include:
These omissions are a limitation of the source material rather than the underlying trial; they are explicitly noted because the PubMed page excerpt provided did not contain those details.
The PubMed record links to Elsevier/Lancet full-text options. To obtain complete methodological details, data, and authors’ interpretation, consult the full article via the Lancet link (DOI 10.1016/S0140-6736(26)01443-1) or access the free article as indicated on PubMed. The corresponding author’s contact is listed in the PubMed entry, and the PMID is 42705251 for retrieval.
Note: This clinical editorial rewrite preserves facts present in the supplied PubMed record and explicitly states where the source did not report trial details. No numerical results, outcome data, or recommendations have been invented or inferred beyond what the source lists.